PORT HUENEME, CA–(Marketwired – Sep 6, 2016) – Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (“KLH”), today announced that the Company will present at the Rodman & Renshaw 18^th Annual Global Investment conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY.

Stellar Biotechnologies Presentation Details:
Conference: Rodman & Renshaw 18th Annual Global Investment Conference
Date:  Tuesday, September 13, 2016
Time:  4:40 p.m. EDT
Location:  Louis (4^th Floor), Lotte New York Palace Hotel
A live webcast of the Company presentation will be available at:
http://wsw.com/webcast/rrshq26/sbot

Investors attending the conferences who would like to schedule a 1-on-1 meeting with Stellar Biotechnologies’ management may do so by contacting their Rodman & Renshaw representatives.

Following the meeting, the webcast will be archived on the Company’s website at: http://ir.stellarbiotechnologies.com/events-calendar

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer’s and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of the Company’s or its partners’ anticipated results, including in connection with clinical trials; the ability to meet the goals of the Company’s joint ventures and strategic partnerships; and other factors referenced in the Company’s filings with securities regulators. For a discussion of further risks and uncertainties related to the Company’s business, please refer to the Company’s public company reports filed with the U.S. Securities and Exchange Commission and the B.C. Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.